Intraocular retinoblastoma

Summary

Intraocular retinoblastoma (MONDO:0003077) is a disease and 7 clinical trials. Top therapeutic interventions include filgrastim, vincristine sulfate, and iodine. A subtype of retinoblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intraocular retinoblastoma
Mondo ID	MONDO:0003077
DOID	DOID:4653
NCIT	C7846
UMLS	C0278717
MedGen	78874
GARD	0023356
Is cancer (heuristic)	no

Also known as: intraocular retinoblastoma

Disease family

This is a subtype of retinoblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › retinal cancer › retinal cell cancer › retinoblastoma › intraocular retinoblastoma

Related subtypes (6): trilateral retinoblastoma, bilateral retinoblastoma, unilateral retinoblastoma, extraocular retinoblastoma, hereditary retinoblastoma, non-hereditary retinoblastoma

Subtypes (1): pediatric intraocular retinoblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00072384	PHASE3	COMPLETED	Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
NCT00079417	PHASE3	COMPLETED	Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
NCT00335738	PHASE3	COMPLETED	Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
NCT03932786	Not specified	RECRUITING	Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT00690469	Not specified	COMPLETED	Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers
NCT00889018	Not specified	UNKNOWN	Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma
NCT03866460	Not specified	COMPLETED	Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FILGRASTIM	4	1
VINCRISTINE SULFATE	4	1
IODINE	3	1